DTx Pharma Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.1B

DTx Pharma General Information

Description

Developer of RNA-based therapeutics designed to aid in personalized treatment across most therapeutic areas. The company's therapeutics use a delivery technology platform that permits efficient delivery of nucleic acid drugs to tissues throughout the body that work in many cell types including neurons, endothelial, and T cells, enabling healthcare providers to deliver oligos in vivo at therapeutically relevant doses.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 10655 Sorrento Valley Road
  • Suite 100
  • San Diego, CA 92121
  • United States
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 10655 Sorrento Valley Road
  • Suite 100
  • San Diego, CA 92121
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DTx Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 14-Jul-2023 $1.1B Completed Generating Revenue
8. Accelerator/Incubator Completed Generating Revenue
7. Early Stage VC 21-Mar-2021 Completed Generating Revenue
6. Grant 13-May-2020 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 06-Jan-2020 Completed Pre-Clinical Trials
4. Grant 01-Jan-2020 Completed Pre-Clinical Trials
3. Grant 15-Sep-2019 Completed Pre-Clinical Trials
2. Angel (individual) 01-Jun-2018 Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Dec-2017 Completed Startup
To view DTx Pharma’s complete valuation and funding history, request access »

DTx Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view DTx Pharma’s complete cap table history, request access »

DTx Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of RNA-based therapeutics designed to aid in personalized treatment across most therapeutic areas. The company
Drug Delivery
San Diego, CA
50 As of 2023

San Diego, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DTx Pharma Competitors (3)

One of DTx Pharma’s 3 competitors is Arcturus Therapeutics Holdings, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arcturus Therapeutics Holdings Formerly VC-backed San Diego, CA
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Avidity Biosciences Formerly VC-backed San Diego, CA
You’re viewing 3 of 3 competitors. Get the full list »

DTx Pharma Patents

DTx Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023091985-A1 Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease Inactive 18-Nov-2021
WO-2023086978-A2 Branched triple lipid-modified nucleic acid compounds Inactive 15-Nov-2021
WO-2023086978-A3 Branched triple lipid-modified nucleic acid compounds Inactive 15-Nov-2021
WO-2023086979-A1 Staggered triple lipid-modified nucleic acid compounds Inactive 15-Nov-2021
WO-2023049716-A1 Compounds targeting nrl for the treatment of retinitis pigmentosa Inactive 21-Sep-2021 C12N15/113
To view DTx Pharma’s complete patent history, request access »

DTx Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DTx Pharma Former Investors (34)

Investor Name Investor Type Holding Investor Since Participating Rounds
Access Biotechnology Corporate Venture Capital Minority
Alzheimer's Association Corporation
Angel (individual) Minority
CMT Research Foundation Not-For-Profit Venture Capital Minority
CONNECT (San Diego) Accelerator/Incubator Minority
You’re viewing 5 of 34 investors. Get the full list »

DTx Pharma FAQs

  • When was DTx Pharma founded?

    DTx Pharma was founded in 2017.

  • Where is DTx Pharma headquartered?

    DTx Pharma is headquartered in San Diego, CA.

  • What is the size of DTx Pharma?

    DTx Pharma has 50 total employees.

  • What industry is DTx Pharma in?

    DTx Pharma’s primary industry is Drug Delivery.

  • Is DTx Pharma a private or public company?

    DTx Pharma is a Private company.

  • What is the current valuation of DTx Pharma?

    The current valuation of DTx Pharma is .

  • What is DTx Pharma’s current revenue?

    The current revenue for DTx Pharma is .

  • How much funding has DTx Pharma raised over time?

    DTx Pharma has raised $112M.

  • Who are DTx Pharma’s investors?

    Access Biotechnology, Alzheimer's Association, , CMT Research Foundation, and CONNECT (San Diego) are 5 of 34 investors who have invested in DTx Pharma.

  • Who are DTx Pharma’s competitors?

    Arcturus Therapeutics Holdings, Alnylam Pharmaceuticals, and Avidity Biosciences are competitors of DTx Pharma.

  • When was DTx Pharma acquired?

    DTx Pharma was acquired on 14-Jul-2023.

  • Who acquired DTx Pharma?

    DTx Pharma was acquired by Novartis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process